Abbott Laboratories: Dividend Hike and Acquisition Speculation Drive Investor Focus
18.12.2025 - 07:51:04Abbott Laboratories US0028241000
Abbott Laboratories has announced an increase to its shareholder payout while simultaneously revealing mixed institutional trading activity. These developments coincide with market rumors regarding a potential acquisition, creating a multifaceted narrative for investors to consider.
The company’s third-quarter results met key expectations. Adjusted earnings per share came in at $1.30, aligning with consensus estimates. Revenue reached $11.37 billion, marking a solid 6.9% year-over-year increase, though it slightly missed projections of $11.40 billion. Management provided a narrowed and confirmed outlook for 2025, forecasting adjusted EPS in the range of $5.12 to $5.18. They anticipate organic sales growth, excluding COVID-19 test-related revenue, to be between 7.5% and 8.0%. Challenges persist in the diagnostics segment, pressured by declining demand for COVID tests Read more...
